复星医药(02196.HK)私有化复宏汉霖(02696.HK)决议案未获股东通过

阿斯达克财经
22 Jan

复星医药(02196.HK) 公布,以吸收合并方式将复宏汉霖(02696.HK) 私有化之特别决议案于H股类别股东大会上未获批准,其中,反对票数约占19.25%,超过收购守则的10%上限。因此,该特别决议案将不会生效,私有化建将不会进行。
复星医药原计划以吸收合并方式将复宏汉霖私有化,每股H股现金价24.6元,涉及总额约32.25亿元;或每股H股发行1股香港存续股份。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-22 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10